Logo image of IMUX

IMMUNIC INC (IMUX) Stock Fundamental Analysis

NASDAQ:IMUX - Nasdaq - US4525EP1011 - Common Stock - Currency: USD

1.27  +0.09 (+7.63%)

After market: 1.27 0 (0%)

Fundamental Rating

2

Taking everything into account, IMUX scores 2 out of 10 in our fundamental rating. IMUX was compared to 572 industry peers in the Biotechnology industry. While IMUX seems to be doing ok healthwise, there are quite some concerns on its profitability. IMUX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMUX has reported negative net income.
IMUX had a negative operating cash flow in the past year.
IMUX had negative earnings in each of the past 5 years.
In the past 5 years IMUX always reported negative operating cash flow.
IMUX Yearly Net Income VS EBIT VS OCF VS FCFIMUX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -149.63%, IMUX is doing worse than 84.90% of the companies in the same industry.
IMUX has a worse Return On Equity (-235.10%) than 70.87% of its industry peers.
Industry RankSector Rank
ROA -149.63%
ROE -235.1%
ROIC N/A
ROA(3y)-111.15%
ROA(5y)-82.52%
ROE(3y)-167.53%
ROE(5y)-118.03%
ROIC(3y)N/A
ROIC(5y)N/A
IMUX Yearly ROA, ROE, ROICIMUX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

IMUX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMUX Yearly Profit, Operating, Gross MarginsIMUX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

IMUX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IMUX has been increased compared to 5 years ago.
IMUX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMUX Yearly Shares OutstandingIMUX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
IMUX Yearly Total Debt VS Total AssetsIMUX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -11.74, we must say that IMUX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.74, IMUX is not doing good in the industry: 77.80% of the companies in the same industry are doing better.
There is no outstanding debt for IMUX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.74
ROIC/WACCN/A
WACCN/A
IMUX Yearly LT Debt VS Equity VS FCFIMUX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.71 indicates that IMUX has no problem at all paying its short term obligations.
IMUX has a Current ratio of 2.71. This is in the lower half of the industry: IMUX underperforms 69.45% of its industry peers.
A Quick Ratio of 2.71 indicates that IMUX has no problem at all paying its short term obligations.
IMUX has a Quick ratio of 2.71. This is in the lower half of the industry: IMUX underperforms 67.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.71
IMUX Yearly Current Assets VS Current LiabilitesIMUX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

IMUX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.15%, which is quite impressive.
EPS 1Y (TTM)62.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 33.02% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.02%
EPS Next 2Y28.68%
EPS Next 3Y19.16%
EPS Next 5Y33.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMUX Yearly Revenue VS EstimatesIMUX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
IMUX Yearly EPS VS EstimatesIMUX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -200 -400 -600 -800 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMUX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMUX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMUX Price Earnings VS Forward Price EarningsIMUX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMUX Per share dataIMUX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as IMUX's earnings are expected to grow with 19.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.68%
EPS Next 3Y19.16%

More info and screens

0

5. Dividend

5.1 Amount

IMUX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNIC INC

NASDAQ:IMUX (2/21/2025, 8:00:01 PM)

After market: 1.27 0 (0%)

1.27

+0.09 (+7.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners59.43%
Inst Owner Change-99.43%
Ins Owners1.01%
Ins Owner Change2.15%
Market Cap114.40M
Analysts83.33
Price Target13.43 (957.48%)
Short Float %4.21%
Short Ratio4.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.87%
Min EPS beat(2)-8.03%
Max EPS beat(2)11.76%
EPS beat(4)2
Avg EPS beat(4)-0.27%
Min EPS beat(4)-13.12%
Max EPS beat(4)11.76%
EPS beat(8)3
Avg EPS beat(8)-14.96%
EPS beat(12)6
Avg EPS beat(12)-8.68%
EPS beat(16)8
Avg EPS beat(16)-14.41%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.98%
PT rev (3m)-0.63%
EPS NQ rev (1m)1.97%
EPS NQ rev (3m)-1.98%
EPS NY rev (1m)0.15%
EPS NY rev (3m)-1.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.78
P/tB 2.78
EV/EBITDA N/A
EPS(TTM)-1.23
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0
BVpS0.46
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -149.63%
ROE -235.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-111.15%
ROA(5y)-82.52%
ROE(3y)-167.53%
ROE(5y)-118.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 354.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.71
Quick Ratio 2.71
Altman-Z -11.74
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)172.06%
Cap/Depr(5y)202.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.94%
EPS Next Y52.02%
EPS Next 2Y28.68%
EPS Next 3Y19.16%
EPS Next 5Y33.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.86%
OCF growth 3YN/A
OCF growth 5YN/A